Potential Cost-Effectiveness Of Vaccination For Rotavirus Gastroenteritis In Eight Latin American And Caribbean Countries

ASU Author/Contributor (non-ASU co-authors, if there are any, appear on document)
Richard Rheingans Ph.D., Department Chair (Creator)
Appalachian State University (ASU )
Web Site: https://library.appstate.edu/

Abstract: Objectives. To estimate the costs, benefits and cost-effectiveness of vaccination for ro-tavirus gastroenteritis in eight Latin American and Caribbean countries: Argentina, Brazil,Chile, the Dominican Republic, Honduras, Mexico, Panama, and Venezuela. Methods.An economic model was constructed to estimate the cost-effectiveness of vaccina-tion from the health care system perspective, using national administrative and published epidemiological evidence, country-specific cost estimates, and vaccine efficacy data. The model was applied to the first five years of life for the 2003 birth cohort in each country. The main health outcome was the disability-adjusted life year (DALY), and the main summary measure was the incremental cost per DALY averted. A 3% discount rate was used for all predictedmcosts and benefits. Sensitivity analyses evaluated the impact of uncertainty regarding key variables on cost-effectiveness estimates. Results. According to the estimates obtained with the economic model, vaccination wouldprevent more than 65% of the medical visits, deaths, and treatment costs associated with rota-virus gastroenteritis in the eight countries analyzed here. At a cost of US$ 24 per course (for a two-dose vaccine), the incremental cost-effectiveness ratio ranged from US$ 269/DALY in Honduras to US$ 10 656/DALY in Chile. Cost-effectiveness ratios were sensitive to assumptions about vaccine price, mortality, and vaccine efficacy. Conclusions Vaccination would effectively reduce the disease burden and health care costsof rotavirus gastroenteritis in the Latin American and Caribbean countries analyzed here.From the health care system perspective, universal vaccination of infants is predicted to becost-effective, based on current standards.

Additional Information

Richard D. Rheingans, Dagna Constenla, Lynn Antil, Bruce L. Innis, and Thomas Breuer (2007) "Potential Cost-Effectiveness Of Vaccination For Rotavirus Gastroenteritis In Eight Latin American And Caribbean Countries" J Pan Am Health Org, 21(4) pp.205-216 Version of Record Available From www.scielosp.org
Language: English
Date: 2007
Rotavirus, rotavirus vaccines, cost-benefit analysis, models, economic, Latin America, Caribbean Region.

Email this document to